Updates are available Correction dated 2024-02-10
Click to view Correction: https://doi.org/10.1007/s40257-024-00850-7
-
Authors
Croft, Michael http://orcid.org/0000-0002-6062-3635
Esfandiari, Ehsanollah
Chong, Camilla
Hsu, Hailing
Kabashima, Kenji http://orcid.org/0000-0002-0773-0554
Kricorian, Greg http://orcid.org/0000-0002-9419-9836
Warren, Richard B. http://orcid.org/0000-0002-2918-6481
Wollenberg, Andreas http://orcid.org/0000-0003-0177-8722
Guttman-Yassky, Emma http://orcid.org/0000-0002-9363-324X
-
Funding
Funding for this research was provided by:
Kyowa Kirin Co., Ltd
Amgen Inc.
- License Information
-
More Information
Article History
Accepted: 13 December 2023
First Online: 18 January 2024
Change Date: 10 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40257-024-00850-7
Declarations
:
: Sponsored by Amgen Inc. and Kyowa Kirin Co., Ltd. Writing support was funded by Amgen Inc. and provided by Jinling Wu, MD, PhD, of Bioscience Communications and Shannon Rao, PhD and Julie Wang, DPM, of Amgen Inc.
: Michael Croft has received consulting fees or speaking honoraria from Amgen, Sanofi, UCB, MedImmune, Millenium, Perseid, Celgene, Novo Nordisk, Merck, Abbvie, Tanabe, Zai Lab, Merrimack, Pfizer, Anaptysbio, Celsius Therapeutics, HifiBio, Kiniksa, Shattuck Labs, Prometheus biosciences, Invectys, Virtici, Capella bioscience, and RAPT therapeutics, and research funds from Kyowa Kirin, Bristol Myers Squib, Janssen, and Eli Lilly. He has licensed patents on OX40 and OX40L. Ehsanollah Esfandiari is an employee of Kyowa Kirin International. Camilla Chong was an employee of Kyowa Kirin International at the time of manuscript development. Hailing Hsu and Greg Kricorian are employees and stockholders of Amgen Inc. Kenji Kabashima has received consulting fees, honoraria, grant support, and/or lecturing fees from Japan Tobacco, LEO Pharma, Maruho, Mitsubishi Tanabe, Ono Pharmaceutical, Procter & Gamble, Sanofi, Taiho, and Torii Pharmaceutical. Richard B. Warren has been a consultant and/or speaker for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly and Company, GlaxoSmithKline, Janssen, LEO Pharma, Novartis, Sanofi Genzyme, and UCB Pharma. Andreas Wollenberg has been an investigator for Beiersdorf, Eli Lilly, Galderma, LEO Pharma, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, and Sanofi; a consultant for AbbVie, Almirall, Anacor Pharmaceuticals, Eli Lilly, Galapagos, Galderma, LEO Pharma, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Sandoz, and Sanofi, and received research grants from Beiersdorf, LEO Pharma, and Pierre Fabre. Emma Guttman-Yassky has received research funds/grants paid to her institution from Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boehringer Ingelheim, Cara Therapeutics, Celgene, Eli Lilly, Innovaderm, Kyowa Kirin, LEO Pharma, Novartis, Pfizer, and Regeneron Pharmaceuticals, and has received consultancy fees from AbbVie, Almirall, Amgen, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, LEO Pharma, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target PharmaSolutions, UCB, and Ventyx Biosciences.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Conception of the article: Greg Kricorian, Hailing Hsu, Camilla Chong, Ehsanollah Esfandiari. Literature search and data analysis: all authors. Drafting, critical revision, and final approval: all authors.
